Workflow
华兰生物疫苗股份有限公司2025年第二次临时股东会决议公告
Shang Hai Zheng Quan Bao·2025-09-22 19:36

Core Viewpoint - The company held its second extraordinary general meeting of shareholders in 2025, where all proposed resolutions were approved without any objections [1][2]. Meeting Details - The meeting took place on September 22, 2025, at 13:30, with both on-site and online voting options available [3][4]. - The total number of shares with voting rights was 595,000,033 [5]. - A total of 152 shareholders participated, representing 487,150,449 shares, which is 81.8740% of the total voting shares [6]. Shareholder Participation - Among the participating shareholders, 150 were small shareholders, representing 28,150,449 shares, or 4.7312% of the total voting shares [7]. - The meeting was presided over by the chairman, Mr. An Kang, and was witnessed by lawyers from Anhui Chengyi Law Firm, who provided a legal opinion confirming the meeting's compliance with regulations [7][8]. Voting Results - The proposal regarding the 2025 mid-term profit distribution plan was approved with 486,923,499 votes in favor, accounting for 99.9534% of the valid votes cast [8]. - Small shareholders voted 27,923,499 shares in favor, representing 99.1938% of the small shareholders' valid votes [8]. Legal Opinion - The legal advisors confirmed that the meeting's procedures, participant qualifications, proposals, voting processes, and results were all in accordance with legal and regulatory requirements [8]. Documents for Reference - The resolutions from the second extraordinary general meeting and the legal opinion from Anhui Chengyi Law Firm are available for review [9].